Antibodies of class Immunoglobulin G (Ig G ) increase protection in HIV vaccine trail, provide a clue for future development of HIV vaccine .
Any vaccines work by inducing production of antibodies against any infective microorganism in our body Incase of HIV, antibodies produced are not able to stop or kill HIV virus as HIV virus proteins keep on changing due to high rate of mutation and keep on presenting variations so that induced antibodies incase of HIV do not confer complete protection against HIV.
Now in a new research conducted by researchers led by Dr. Barton F. Haynes from Duke University, it is found that higher concentration of particular antibodies belonging to class Immunoglobulin G (Ig G ) have imparted increased protection in individuals who had participated in a clinical research on HIV vaccine conducted at Thailand in 2009, about 1600 volunteers participated in clinical trial on HIV vaccine.
About 31 % population which received an experimental HIV vaccine had lower chance of getting HIV infection compared to individuals given only placebo control group.
Dr. Barton F. Haynes of Duke University and his team analyzed serum samples from 246 vaccinated volunteers and it was found that there is higher concentration of Ig G concentration in individuals which showed increased protection, and there was high concentration of Ig A antibodies in volunteers which were not shown protection.
Ig G antibodies attach to variable regions V1 V2 on gp120 protein which help HIV virus in the process of attachment to host cell.
Increase concentration of Ig A antibodies in individuals which did not show any protection might be due to hampering of activity of Ig G antibodies, by attaching at C1, first constant region.
NIAID Director Dr. Anthony S. Fauci has expressed hopes for developing a successful vaccine against HIV in near future by using present findings.
Authored by : B V Waghmare
Last updated: 20-4-2012